These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
898 related articles for article (PubMed ID: 22676551)
1. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction. Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551 [TBL] [Abstract][Full Text] [Related]
2. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258 [TBL] [Abstract][Full Text] [Related]
3. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status. Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529 [TBL] [Abstract][Full Text] [Related]
4. Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials. Sohal DP; Rice TW; Rybicki LA; Rodriguez CP; Videtic GM; Saxton JP; Murthy SC; Mason DP; Phillips BE; Tubbs RR; Plesec T; McNamara MJ; Ives DI; Bodmann JW; Adelstein DJ Dis Esophagus; 2015; 28(6):547-51. PubMed ID: 24849395 [TBL] [Abstract][Full Text] [Related]
5. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M; Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164 [TBL] [Abstract][Full Text] [Related]
6. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. Cinar P; Calkins SM; Venook AP; Kelley RK Anticancer Res; 2014 Dec; 34(12):7357-60. PubMed ID: 25503172 [TBL] [Abstract][Full Text] [Related]
7. A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction. McNamara MJ; Adelstein DJ; Bodmann JW; Greskovich JF; Ives DI; Mason DP; Murthy SC; Rice TW; Saxton JP; Sohal D; Stephans K; Rodriguez CP; Videtic GM; Rybicki LA J Thorac Oncol; 2014 Oct; 9(10):1561-7. PubMed ID: 25170643 [TBL] [Abstract][Full Text] [Related]
8. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195 [TBL] [Abstract][Full Text] [Related]
9. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651 [TBL] [Abstract][Full Text] [Related]
10. High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma. Bichev D; Treese C; von Winterfeld M; Breithaupt K; Dogan Y; Schmidt SC; Daum S; Thuss-Patience PC Oncology; 2015; 89(2):95-102. PubMed ID: 25823985 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. Rodriguez CP; Adelstein DJ; Rice TW; Rybicki LA; Videtic GM; Saxton JP; Murthy SC; Mason DP; Ives DI J Thorac Oncol; 2010 Feb; 5(2):229-35. PubMed ID: 20009775 [TBL] [Abstract][Full Text] [Related]
12. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy. Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159 [TBL] [Abstract][Full Text] [Related]
13. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma. van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441 [TBL] [Abstract][Full Text] [Related]
15. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma]. Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285 [TBL] [Abstract][Full Text] [Related]
16. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India. Nadaf AS; Rani H; Dinesh US Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704 [TBL] [Abstract][Full Text] [Related]
17. HER2 expression in carcinomas of the true cardia (Siewert type II esophagogastric junction carcinoma). Katai H; Ishida M; Yamashita H; Ohashi M; Morita S; Katayama H; Fukagawa T; Kushima R World J Surg; 2014 Feb; 38(2):426-30. PubMed ID: 24114368 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers. Park DJ; Yoon C; Thomas N; Ku GY; Janjigian YY; Kelsen DP; Ilson DH; Goodman KA; Tang LH; Strong VE; Coit DG; Yoon SS Ann Surg Oncol; 2014 Apr; 21(4):1130-7. PubMed ID: 24370903 [TBL] [Abstract][Full Text] [Related]
19. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH. Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]